Pharmacogenomics of psychiatric drug treatment

David Pickar

Research output: Contribution to journalArticle

Abstract

It is the goal of pharmacogenomics in psychiatry to establish predictive relationships between polymorphisms of candidate genes and therapeutic response to drug treatment. Polymorphisms of candidate genes related to drug mechanisms and pathophysiology of illness and defined clinical phenotype are the foundations for pharmacogenomic studies. Pharmacogenomic studies of antipsychotic response have focused on polymorphisms of genes for dopamine and serotonin receptors with most positive results reported for polymorphisms of genes of the 5HT2a and 5HT2c serotonin receptor subtypes. Although the goal of establishing individualized medicine predicated on an individual patient's genetic code has yet to be achieved, the fundamentals are now in place for second-generation investigation and more application to health care.

Original languageEnglish (US)
Pages (from-to)303-321
Number of pages19
JournalPsychiatric Clinics of North America
Volume26
Issue number2
DOIs
StatePublished - Jun 2003
Externally publishedYes

Fingerprint

Pharmacogenetics
Psychiatry
Serotonin Receptors
Pharmaceutical Preparations
Genes
Genetic Code
Precision Medicine
Dopamine Receptors
Therapeutics
Antipsychotic Agents
Delivery of Health Care
Phenotype
Pharmacogenomic Testing

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Pharmacogenomics of psychiatric drug treatment. / Pickar, David.

In: Psychiatric Clinics of North America, Vol. 26, No. 2, 06.2003, p. 303-321.

Research output: Contribution to journalArticle

Pickar, David. / Pharmacogenomics of psychiatric drug treatment. In: Psychiatric Clinics of North America. 2003 ; Vol. 26, No. 2. pp. 303-321.
@article{fd0022992f754e99affe0dc9821bf952,
title = "Pharmacogenomics of psychiatric drug treatment",
abstract = "It is the goal of pharmacogenomics in psychiatry to establish predictive relationships between polymorphisms of candidate genes and therapeutic response to drug treatment. Polymorphisms of candidate genes related to drug mechanisms and pathophysiology of illness and defined clinical phenotype are the foundations for pharmacogenomic studies. Pharmacogenomic studies of antipsychotic response have focused on polymorphisms of genes for dopamine and serotonin receptors with most positive results reported for polymorphisms of genes of the 5HT2a and 5HT2c serotonin receptor subtypes. Although the goal of establishing individualized medicine predicated on an individual patient's genetic code has yet to be achieved, the fundamentals are now in place for second-generation investigation and more application to health care.",
author = "David Pickar",
year = "2003",
month = "6",
doi = "10.1016/S0193-953X(02)00109-0",
language = "English (US)",
volume = "26",
pages = "303--321",
journal = "Psychiatric Clinics of North America",
issn = "0193-953X",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Pharmacogenomics of psychiatric drug treatment

AU - Pickar, David

PY - 2003/6

Y1 - 2003/6

N2 - It is the goal of pharmacogenomics in psychiatry to establish predictive relationships between polymorphisms of candidate genes and therapeutic response to drug treatment. Polymorphisms of candidate genes related to drug mechanisms and pathophysiology of illness and defined clinical phenotype are the foundations for pharmacogenomic studies. Pharmacogenomic studies of antipsychotic response have focused on polymorphisms of genes for dopamine and serotonin receptors with most positive results reported for polymorphisms of genes of the 5HT2a and 5HT2c serotonin receptor subtypes. Although the goal of establishing individualized medicine predicated on an individual patient's genetic code has yet to be achieved, the fundamentals are now in place for second-generation investigation and more application to health care.

AB - It is the goal of pharmacogenomics in psychiatry to establish predictive relationships between polymorphisms of candidate genes and therapeutic response to drug treatment. Polymorphisms of candidate genes related to drug mechanisms and pathophysiology of illness and defined clinical phenotype are the foundations for pharmacogenomic studies. Pharmacogenomic studies of antipsychotic response have focused on polymorphisms of genes for dopamine and serotonin receptors with most positive results reported for polymorphisms of genes of the 5HT2a and 5HT2c serotonin receptor subtypes. Although the goal of establishing individualized medicine predicated on an individual patient's genetic code has yet to be achieved, the fundamentals are now in place for second-generation investigation and more application to health care.

UR - http://www.scopus.com/inward/record.url?scp=0038586364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038586364&partnerID=8YFLogxK

U2 - 10.1016/S0193-953X(02)00109-0

DO - 10.1016/S0193-953X(02)00109-0

M3 - Article

C2 - 12778835

AN - SCOPUS:0038586364

VL - 26

SP - 303

EP - 321

JO - Psychiatric Clinics of North America

JF - Psychiatric Clinics of North America

SN - 0193-953X

IS - 2

ER -